{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PFS", "query": { "intervention": "PFS" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 555, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PFS&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T20:52:52.259Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03083808", "title": "Phase II Trial of Continuation Therapy in Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Greg Durm, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-20", "completion_date": "2022-03-03", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083808" }, { "nct_id": "NCT07007091", "title": "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 260, "start_date": "2025-06-12", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 4, "location_summary": "Miami, Florida • Grayslake, Illinois • Las Vegas, Nevada + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Grayslake", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007091" }, { "nct_id": "NCT02806219", "title": "Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Prefilled syringe (PFS)", "type": "DEVICE" }, { "name": "e-Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 100, "start_date": "2016-03", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2016-11-17", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02806219" }, { "nct_id": "NCT05805605", "title": "Allo HSCT Using RIC and PTCy for Hematological Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myelodysplastic Syndromes", "Leukemia, Myeloid", "Myelodysplastic Syndrome With Excess Blasts-1", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Myeloproliferative Neoplasm", "Myelofibrosis" ], "interventions": [ { "name": "Peripheral Blood Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Allopurinol 300 MG", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bone Marrow Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Sirolimus Pill", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 56, "start_date": "2023-05-01", "completion_date": "2028-10-22", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05805605" }, { "nct_id": "NCT03542877", "title": "Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oral Tablet: Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic Thoracic Oncology Medical Investigators Consortium", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 44, "start_date": "2018-06-01", "completion_date": "2022-03-07", "has_results": true, "last_update_posted_date": "2022-07-15", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 10, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03542877" }, { "nct_id": "NCT00992446", "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Diffuse Large B-Cell Lymphoma", "B-Cell Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Non-Hodgkin Lymphoma", "T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-09-02", "completion_date": "2019-10-29", "has_results": true, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00992446" }, { "nct_id": "NCT06249165", "title": "VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Inclisiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2024-12-16", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hiram", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06249165" }, { "nct_id": "NCT05274100", "title": "Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 394, "start_date": "2020-09-01", "completion_date": "2021-07-06", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 8, "location_summary": "Anaheim, California • Cypress, California • Miami, Florida + 5 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274100" }, { "nct_id": "NCT02658487", "title": "Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia With Multilineage Dysplasia", "Myeloid Sarcoma", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Vosaroxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-03", "completion_date": "2024-09", "has_results": true, "last_update_posted_date": "2025-04-15", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Charleston, South Carolina • Nashville, Tennessee", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658487" }, { "nct_id": "NCT03009201", "title": "Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Soft Tissue Sarcoma", "Locally Advanced Angiosarcoma", "Locally Advanced Leiomyosarcoma", "Locally Advanced Liposarcoma", "Locally Advanced Malignant Peripheral Nerve Sheath Tumor", "Locally Advanced Myxofibrosarcoma", "Locally Advanced Undifferentiated Pleomorphic Sarcoma", "Metastatic Angiosarcoma", "Metastatic Epithelioid Sarcoma", "Metastatic Fibrosarcoma", "Metastatic Liposarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Myxofibrosarcoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Pleomorphic Rhabdomyosarcoma", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Undifferentiated (Embryonal) Sarcoma", "Unresectable Leiomyosarcoma", "Unresectable Liposarcoma", "Unresectable Malignant Peripheral Nerve Sheath Tumor", "Unresectable Soft Tissue Sarcoma", "Unresectable Synovial Sarcoma", "Unresectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 16, "start_date": "2017-03-10", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-09-11T20:52:52.259Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03009201" } ] }